Complexa is a clinical-stage biopharmaceutical company based in Berwyn, Pennsylvania, founded in 2008. The company focuses on advancing therapeutic innovation in human cell signaling for inflammation, fibrosis, and CNS disease treatment solutions. Complexa's pioneering approach revolves around the synthesis and therapeutic application of endogenous nitro-fatty acids (NFAs) and related mediators, with the aim of treating various prevalent inflammatory, fibrotic, and CNS diseases.
The company's proprietary technologies leverage their expertise in identifying and synthesizing these mediators to enhance the body's own anti-inflammatory and metabolic signaling mechanisms. This, in turn, supports the resolution and repair of both acute and chronic tissue injuries and diseases. Complexa recently secured a $62.00M Series C investment on 26 July 2017, with participation from prominent investors including New Enterprise Associates, HBM Healthcare Investments, Riverfront Ventures, Andera Partner, Pfizer Venture Investments, Jafco Life Science, and Edmond de Rothschild Private Equity.
